Bio-Me AS appoints Dr. Davide Manissero to Board of Directors to accelerate women's health diagnostics strategy

Bio-Me AS, a microbiome company pioneering Precision Microbiome Profiling (PMP™) and building a pipeline of microbiome-based molecular diagnostics for women's health, announced the appointment of Dr. Davide Manissero, MD, to its Board of Directors.

Dr. Manissero previously served as Chief Medical Officer at QIAGEN and is currently Vice President and Chief Medical Officer at Radiometer (a Danaher company). He has also held leadership roles at ECDC and served as a Medical Officer for the WHO in South-East Asia.

“Microbiome-driven diagnostics are poised to close longstanding gaps in women's health. Bio-Me's PMP™ platform — with its focus on short turnaround time and absolute quantification of targeted microbial signatures — offers a compelling path from analytical rigor to clinical utility,” said Dr. Manissero.

Near-term priorities

• Clinical evidence programmes to correlate quantified vaginal microbiome signatures with diagnosis, risk stratification and treatment guidance.
• Regulatory strategy and quality systems aligned with EU IVDR and U.S. pathways.
• Medical affairs engagement with clinicians, guideline bodies and payers.